Share on StockTwits
 

Investment analysts at Imperial Capital initiated coverage on shares of Lifevantage (NASDAQ:LFVN) in a note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set an “in-line” rating and a $2.10 price target on the stock. Imperial Capital’s target price suggests a potential upside of 38.16% from the company’s current price.

The analysts wrote, “We are initiating coverage of LifeVantage Corporation (LFVN) with an In-Line rating and one-year price target of $2.10. Our price target is about 40% above the recent share price. LFVN’s business has experienced rapid revenue growth since FY09 as the company transitioned from retail store distribution to a network marketing (multi-level marketing) model for its anti-aging nutraceutical product, Protandim. Our In-Line rating reflects some near-term caution for two reasons: 1) revenue growth has declined in the last two quarters, in part, due to a slowdown in active distributor growth and a weakening Japanese yen, 2) near-term visibility is clouded as the company has lost near-term distributor momentum which we believe is critical in a multi-level marketing model. LFVN’s recent additions to management and initiatives to revive distributor and active customer growth look positive; however, we prefer to have more visibility before committing to these shares, which currently trade consistent with its multi-level marketing peers.”

Lifevantage (NASDAQ:LFVN) traded down 4.76% on Wednesday, hitting $1.40. The stock had a trading volume of 890,797 shares. Lifevantage has a 1-year low of $1.60 and a 1-year high of $3.85. The stock has a 50-day moving average of $2.48 and a 200-day moving average of $2.39. The company has a market cap of $145.5 million and a P/E ratio of 16.70.

Lifevantage (NASDAQ:LFVN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.03 earnings per share (EPS) for the quarter. Analysts expect that Lifevantage will post $0.10 EPS for the current fiscal year.

Lifevantage Corporation (NASDAQ:LFVN) is engaged in the identification, research, development, manufacture and distribution of advanced nutraceutical dietary supplements, including its product, Protandim, the Nrf2 Synergizer and its anti-aging skin care product, LifeVantage TrueScience.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.